We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cover-Glass Test Differentiates Bacteria

By LabMedica International staff writers
Posted on 23 May 2012
A simple and cost-effective cover-glass test differentiates between micrococci and pathogenic staphylococci in the clinical laboratory. More...


A cover-glass placed on a heavily inoculated culture plate clearly differentiates facultative anaerobic staphylococci growing underneath the cover-glass after overnight incubation from nongrowing aerobic micrococci.

Medical microbiologists at the Charles University (Prague, Czech Republic) used a study set that included 18 strains of Micrococcus luteus as the most common micrococcal species isolated from clinical specimens and indoor air, 15 strains of Staphylococcus aureus as a significant pathogen, and 20 strains of other staphylococcal species to test the cover-glass method.

To carry out the cover-glass test, a sterile cover-glass was placed with a pair of sterile tweezers onto a heavily inoculated area of the Columbia blood agar plate (Merck; Darmstadt, Germany) with a clinical specimen or bacterial culture and after overnight incubation at 37 °C, the plate was checked for pigmented colonies or bacterial biomass underneath the cover glass.

The result was classified as strongly positive if an unaffected growth was observed beneath the cover glass, moderately positive if the growth was affected and weakly positive if a fine growth occurred. A negative result meant that the strain was not able to grow beneath the coverslip. Each strain was also tested for antibiotic resistance. All S. aureus strains analyzed were positive in the cover-glass test in contrast to the strains from the genus Micrococcus or related genera such as Dermacoccus, Kytococcus, and Kocuria, that remained negative, except for one Kocuria kristinae strain. Seven of 35 staphylococcal strains tested were cover-glass negative.

The cover-glass test proved rapid, highly specific, easy to perform, and easy to interpret. It should be used in combination with the furazolidone and bacitracin disks in both primary and secondary culture as a useful tool for differentiating S. aureus and other staphylococci of human origin from Micrococcus species or related genera. Additional screening tests such as Gram-staining and plasma-coagulase test, and biochemical or matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry identification approaches may need to be performed to identify clinical isolates of catalase-positive cocci to the species level. The study was published in the June 2012 issue of the Journal of Microbiological Methods.

Related Links:

Charles University
Merck




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.